ERBB2 and breast carcinoma: The estrogen response early score in ER-positive/human epidermal receptor 2 (HER2)-negative breast cancer, determined by immunohistochemistry, was highest compared to the other subtypes in the TCGA and METABRIC cohorts (Figure 1A; both p < 0.001).